Sugi Predict

Sugi Predict / Targets / PLAT

PLAT

Tissue-type plasminogen activator · P00750 · PLAT on Sugi Atlas →

51,306 patent compounds predicted against PLAT, 32,368 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL312480 SCHEMBL312480 0.56 19/20
SCHEMBL313149 SCHEMBL313149 0.55 16/20
SCHEMBL312438 SCHEMBL312438 0.48 15/20
SCHEMBL257430 SCHEMBL257430 0.61 13/20
SCHEMBL257296 SCHEMBL257296 0.53 12/20
SCHEMBL256944 SCHEMBL256944 0.51 12/20
SCHEMBL257326 SCHEMBL257326 0.68 11/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL460431) 0.52 11/20
SCHEMBL419839 SCHEMBL419839 0.59 9/20
SCHEMBL102985 SCHEMBL102985 0.58 8/20
SCHEMBL256819 SCHEMBL256819 0.64 6/20
SCHEMBL257522 SCHEMBL257522 0.62 6/20
Nafamostat Nafamostat (SCHEMBL135503) 0.54 6/20
SCHEMBL257699 SCHEMBL257699 0.48 6/20
SCHEMBL478576 SCHEMBL478576 0.75 5/20
SCHEMBL478578 SCHEMBL478578 0.75 5/20
SCHEMBL478480 SCHEMBL478480 0.66 5/20
SCHEMBL478482 SCHEMBL478482 0.66 5/20
SCHEMBL103383 SCHEMBL103383 0.56 5/20
SCHEMBL257693 SCHEMBL257693 0.55 5/20

Clinical trials — most relevant to PLAT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography PHASE4UNKNOWN
Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section PHASE4COMPLETED
Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window PHASE4COMPLETED
Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries PHASE3COMPLETED
Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST) PHASE3COMPLETED
Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER) PHASE3COMPLETED
A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion PHASE2COMPLETED
Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA) PHASE2UNKNOWN
Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage PHASE2UNKNOWN
The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers PHASE2COMPLETED
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection PHASE2COMPLETED
Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure PHASE2RECRUITING
Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid Surgery PHASE1COMPLETED
Study of Aspirin and TPA in Acute Ischemic Stroke PHASE1WITHDRAWN
A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion PHASE1COMPLETED
A Lifestyle Intervention to Improve in Vitro Fertilization Results nanUNKNOWN
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery nanENROLLING_BY_INVITATION
Surgical Revascularisation and Nerve Stimulation Trial nanWITHDRAWN
Genetic Architecture of Plasma T-PA and PAI-1 nanCOMPLETED
Study to Assess the Changes in Blood Clotting Factors and Blood Vessel Wall Function in Obstructive Sleep Apnea nanCOMPLETED
Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease nanRECRUITING
Defining the Temporal Changes in the Acute Phase Response During Graded Exercise: A Prospective Study nanENROLLING_BY_INVITATION
The Diagnostic and Prognostic Value of TAT, PIC, tPAI·C and TM in Sepsis-induced Coagulopathy nanUNKNOWN
Peripheral Vascular Disease and Nerve Stimulation nanCOMPLETED
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence nanWITHDRAWN
Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Non-cardiac Surgery (SPARSE) nanCOMPLETED
SuPAR in Adult Patients With Covid-19 nanCOMPLETED
The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation nanUNKNOWN
Gap Junction Potentiation of Endothelial Function With Rotigaptide nanCOMPLETED
Blood Factors and Peripheral Arterial Disease Outcomes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PLAT binder may also engage these)

ProteinNameSimilarity
P49150 — 1.000 P49150 →
Q5R8J0 — 1.000 Q5R8J0 →
P19637 — 1.000 P19637 →
P11214 — 1.000 P11214 →
P15638 — 1.000 P15638 →
Q5E9Z2 — 0.998 Q5E9Z2 →
Q8SQ23 — 0.997 Q8SQ23 →
Q28198 — 0.997 Q28198 →
Q08048 — 0.996 Q08048 →
P04185 — 0.995 P04185 →
Q7RTY8 — 0.994 Q7RTY8 →
P29598 — 0.994 P29598 →
Q8MHY7 — 0.994 Q8MHY7 →
Q6L711 — 0.994 Q6L711 →
P98119 — 0.993 P98119 →
O18783 — 0.993 O18783 →
P26928 — 0.992 P26928 →
P16227 — 0.992 P16227 →
F10 Coagulation factor X 0.992 landscape →
P86091 — 0.992 P86091 →
Q5G265 — 0.992 Q5G265 →
Q2F9P2 — 0.992 Q2F9P2 →
P70375 — 0.992 P70375 →
P98121 — 0.992 P98121 →
Q28661 — 0.991 Q28661 →
Q05589 — 0.991 Q05589 →
Q58L94 — 0.991 Q58L94 →
PLAU Urokinase-type plasminogen activator 0.990 landscape →
P18292 — 0.990 P18292 →
P12545 — 0.990 P12545 →